Next Article in Journal
Editorial for Special Issue “Image Analysis and Machine Learning in Cancers”
Next Article in Special Issue
Does the Organ Matter in PTLD Development in Solid Organ Transplant Recipients? A Multicenter Observational Study of Risk and Prognostic Factors
Previous Article in Journal
Modern Therapeutic Approaches in Anaplastic Thyroid Cancer: A Meta-Analytic Review of Randomised and Single Arm Studies on Efficacy and Survival
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 17
Issue 5
10.3390/cancers17050773
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Expanding Indications in Transplant Oncology

Cancers 2025, 17(5), 773; https://doi.org/10.3390/cancers17050773
by Erlind Allkushi, Chase J. Wehrle, JaeKeun Kim, Mazhar Khalil, David C. H. Kwon, Masato Fujiki, Antonio D. Pinna, Charles Miller, Andrea Schlegel, Federico Aucejo, Koji Hashimoto and Alejandro Pita *
Reviewer 1:
Eugene Schiff
Reviewer 2: Anonymous
Cancers 2025, 17(5), 773; https://doi.org/10.3390/cancers17050773
Submission received: 20 January 2025 / Revised: 16 February 2025 / Accepted: 20 February 2025 / Published: 25 February 2025
(This article belongs to the Special Issue Cancer Risk Factors and Prognosis in Transplant Patients)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

This literature reviw provides a summary of the literature on treatment protocolsthat may treatment of for HCC with liver trans plantation that is timely and well done. However there is now evidence that non-alcoholic steatohepatitis , which is a misnomer, is the most common cause of cirrhosis and HCC. Clearly early liver transplantatin is potentially life saving.Your group concludes that both cholangiocarcinoma and HCC  treatment in conjunction with new therapies are possible. Has  your team in Romania prospectively collaborated with other center in clinical trials? Futhermore as you undoubtedly know there is growing evidence the any amount of alcohol is associated with a risk of malignancies including HCC and cholangiocarcinoma.

Author Response

see attached

Author Response File: Author Response.docx

Reviewer 2 Report

Comments and Suggestions for Authors

Authors aimed to describe the evidence supporting expanding indications and selection criteria for liver transplantation for various oncologic       

indications of primary and secondary liver tumors. This is an interesting paper.

There are several minor concerns to be addressed.

1) The reason why advanced HCC is not generally considered as liver transplantation candidate is the high probability of recurrence.

There are limited option for HCC recurrence after liver transplantation. So, the salvage treatment regimen should be summarized in the era of molecular target agent.

2) The role of so called "neoadjuvant chemo and/or radiotherapy" for downstaging should be addressed further. 

In particular, the role of radiotherapy (internal or external ) combined with use of novel immune-checkpoint inhibitor should be addressed.

Author Response

see attached

Author Response File: Author Response.docx

Back to TopTop